Spectrum of Neurocognitive Disorders Explorer

Module 1 • Prodromal Dynamic Architecture

The Natural History & Trajectories of Mild Cognitive Impairment

This section details the transitional state between normal neurobiological aging and overt dementia. Users can explore domain-specific trajectories of cognitive decline, examine the non-linear dynamics of conversion versus reversion, and interact with predictive features including entorhinal cortex morphometry and CART decision models derived from serial measurements.

Domain-Specific Prodromal Trajectories

Mathematical Modeling

Delayed recall, working memory, and spatial memory follow a quadratic function with steep precipitous drops prior to conversion, while executive functions decline linearly.

Click dataset legend above to toggle specific cognitive domains Multi-domain Amnestic MCI = Highest AD Risk

⚡ The Reversion Phenomenon (14% - 42%)

MCI trajectory is not strictly linear. Over 18–60 months, up to 42% of community cases revert to normal. CART analysis reveals that serial testing prevents misclassifying fluctuating cases as stable.

Primary Causes of Reversion: Resolution of transient systemic illnesses, treatment of severe depressive episodes, or fluctuating cerebral amyloid angiopathy (CAA).

CART Accuracy: 78.6% predictive accuracy in endpoint status using longitudinal tracking.

🧠 MRI Morphometric Predictor Tool

Support vector machine (SVM) models identify key structural thresholds (86% accuracy) predicting MCI conversion to Alzheimer's Disease.

Right Entorhinal Cortical Volume: 1250 mm³

Module 2 • Pathophysiology, Staging Continuum & Standard Symptomatic Pharmacotherapy

Alzheimer's Disease (AD): Core Clinical Deep Dive

Alzheimer's disease accounts for 60%–70% of all neurocognitive disorders. It is defined pathologically by extracellular amyloid-beta ($A\beta$) plaque deposition and intracellular hyperphosphorylated tau neurofibrillary tangles (NFTs), culminating in progressive synaptic disruption, basal forebrain cholinergic loss, and widespread neurodegeneration. Explore the classic Jack et al. Biomarker Cascade Model, standard clinical staging (CDR 0–3), genetic etiology, and standard symptomatic pharmacotherapy titration schedules.

Jack et al. Dynamic Biomarker Cascade Model

Temporal Trajectory

Biomarkers become abnormal sequentially over decades prior to clinical dementia: CSF $A\beta_{42}$ drops & Amyloid PET rises first, followed by p-tau217/Tau PET, FDG-PET hypometabolism, volumetric MRI atrophy, and finally overt clinical disability.

Click dataset labels in legend to isolate specific biomarker curves Preclinical Latency: 15-20 Years

🧬 Genetics: Deterministic vs Risk Genes

Early-Onset Familial AD (<1% of cases, onset <65 yrs): Autosomal dominant mutations in APP (Chrom 21), PSEN1 (Chrom 14), or PSEN2 (Chrom 1). Almost 100% penetrance; drives overproduction of toxic $A\beta_{42}$.

Late-Onset Sporadic AD (>99% of cases): Major susceptibility gene is APOE (Chrom 19). Single $\epsilon 4$ allele increases risk 3–4x; dual $\epsilon 4/\epsilon 4$ increases risk 8–12x by impairing amyloid clearance.

⚡ The Triad of Neurodegeneration

Cholinergic Deficit: Degeneration of nucleus basalis of Meynert leads to profound central acetylcholine (ACh) loss, disrupting memory consolidation.
Glutamatergic Excitotoxicity: Tonic low-level NMDA receptor activation by excess extracellular glutamate causes pathological calcium inflow and synaptic death.
Neuroinflammation: Microglial activation and GFAP reactive astrogliosis amplify inflammatory cytokine cascade ($IL-1\beta, TNF-\alpha$).

📊 Interactive AD Clinical Staging & Clinical Dementia Rating (CDR) Continuum

Select a disease stage to inspect characteristic cognitive scores, clinical features, functional independence, and recommended care targets.

Standard Symptomatic Pharmacotherapy Matrix

Acetylcholinesterase Inhibitors (AChEIs) & NMDA Receptor Antagonists for Cognitive Support

Symptomatic (Non-Disease Modifying)

Donepezil (Aricept) AChEI

Indication: Mild, Moderate, & Severe AD Dementia.

Titration: Start 5 mg QD at bedtime x 4–6 weeks; increase to target 10 mg QD.

Side Effects: Nausea, diarrhea, insomnia, bradycardia, muscle cramps.

Rivastigmine (Exelon) AChEI + BuChEI

Indication: Mild to Moderate AD & Parkinson's Dementia.

Titration: Transdermal Patch: 4.6 mg/24h x 4 weeks $\rightarrow$ 9.5 mg/24h target.

Advantage: Transdermal patch bypasses GI tract, significantly lowering nausea.

Galantamine (Razadyne) AChEI + PAM

Indication: Mild to Moderate AD Dementia.

Titration: ER: Start 8 mg QD x 4 weeks $\rightarrow$ 16 mg QD target $\rightarrow$ Max 24 mg QD.

Dual Action: Inhibits AChE plus allosterically modulates nicotinic ACh receptors.

Memantine (Namenda) NMDA Antagonist

Indication: Moderate to Severe AD Dementia (Monotherapy or + AChEI).

Titration: Start 5 mg QD; increase by 5 mg weekly to target 10 mg BID (20 mg/day).

Mechanism: Uncompetitive low-affinity NMDA blocker; prevents glutamate excitotoxicity.

Module 3 • Alpha-Synucleinopathy & Synaptic Dysfunction

Dementia with Lewy Bodies (DLB): Clinical & Diagnostic Deep Dive

Dementia with Lewy Bodies (DLB) represents the second most common cause of neurodegenerative dementia (~15% of cases). Pathologically defined by abnormal intraneuronal aggregates of alpha-synuclein (Lewy bodies and Lewy neurites) concentrated in subcortical nuclei, limbic regions, and neocortex. This dedicated module features the McKeith 2017 Diagnostic Evaluator, a comparative DLB vs AD vs PDD Radar Chart, biofluid/imaging biomarker profiles, and critical neuroleptic sensitivity rules.

Clinical Spectrum Comparison: DLB vs AD vs PDD

Phenotypic Profile

This radar profile illustrates distinct clinical domains: DLB features early visual hallucinations, cognitive fluctuations, and RBD with relative memory sparing compared to AD.

The "1-Year Rule": Parkinsonism >1 yr prior to dementia = PDD; Dementia concurrent/first = DLB.

📋 McKeith 2017 Interactive DLB Diagnostic Evaluator

Check patient clinical features and biomarker findings to calculate diagnostic probability according to consensus standards.

Core Clinical Features: Fluctuating Cognition (pronounces variations in attention/alertness) Recurrent Visual Hallucinations (well-formed, detailed, 73% cases) REM Sleep Behavior Disorder (RBD - complex dream enactment) Spontaneous Parkinsonism (bradykinesia, resting tremor, rigidity)

Indicative Biomarkers: Reduced Dopamine Transporter uptake (DaT-SPECT / FP-CIT) Abnormal 123I-MIBG Myocardial Scintigraphy (sympathetic denervation) Polysomnographic (PSG) confirmation of REM sleep without atonia

🔬 Advanced DLB Biomarker Frontier

Alpha-Synuclein Seed Amplification Assay (αSyn-SAA):

Dramatically changed diagnostic precision. Detects misfolded alpha-synuclein seeds in CSF or dermal nerve biopsies with >90% sensitivity and specificity prior to overt motor symptoms.

EEG Cingulate Island Sign (CIS):

FDG-PET shows preserved posterior cingulate metabolism relative to precuneus and cuneus atrophy, distinguishing DLB from AD.

🚨 Severe Neuroleptic Sensitivity & Management Rules High Mortality Risk

Up to 50% of DLB patients exposed to typical antipsychotics (e.g., Haloperidol) experience catastrophic reactions: sudden irreversible parkinsonism, neuroleptic malignant syndrome (NMS), or autonomic collapse.

1. Hallucinations First-Line: AChEIs (Rivastigmine/Donepezil) often resolve visual hallucinations without motor worsening.

2. Psychosis Alternative: Pimavanserin (selective 5-HT2A inverse agonist) or low-dose Quetiapine if AChEIs fail. Avoid Risperidone/Olanzapine.

3. RBD Management: Melatonin (3–12 mg) or low-dose Clonazepam (0.25–1 mg) at bedtime.

Module 4 • Frontotemporal Lobar Degeneration (FTLD) Spectrum

Frontotemporal Dementia (FTD): Presentation, Subtypes & Genetics

Frontotemporal Dementia encompasses a heterogeneous group of non-Alzheimer neurodegenerative disorders characterized by progressive atrophy of the frontal and/or temporal lobes. Representing up to 10%–20% of early-onset dementias (age <65), FTD presents marked clinical diversity spanning behavioral alterations, primary progressive aphasias (PPA), and motor neuron dysfunction. Pathologically driven by inclusions of hyperphosphorylated Tau (FTLD-Tau), TDP-43 (FTLD-TDP), or FUS (FTLD-FUS).

C9orf72 Expansion FTLD-TDP

Most common genetic cause of familial FTD and ALS (hexanucleotide GGGGCC repeat expansion). Drives both bvFTD and FTD-ALS phenotypes.

MAPT Mutation FTLD-Tau

Microtubule-associated protein tau gene mutation on Chromosome 17. Leads to hyperphosphorylated 3R/4R tau aggregation, presenting primarily as bvFTD or PSP/CBD.

GRN Mutation FTLD-TDP

Progranulin gene mutation causing haploinsufficiency and ubiquitin/TDP-43 positive neuronal inclusions. Often presents as bvFTD or nonfluent PPA.

Interactive FTD Clinical Subtype Explorer

Select a subtype to inspect clinical features, neuroimaging signature, speech patterns, and underlying pathology.

6 Major Variants

🔍 Rascovsky Criteria Evaluator for Behavioral Variant FTD

Possible bvFTD requires $\ge 3$ of 6 core behavioral/cognitive features. Probable bvFTD requires functional decline + frontal/temporal MRI or PET abnormality.

1. Early Behavioral Disinhibition (socially inappropriate actions, loss of manners) 2. Early Apathy or Inertia (loss of initiative, drive, or interest) 3. Early Loss of Sympathy or Empathy (unresponsive to others' feelings) 4. Early Perseverative, Stereotyped or Compulsive Behavior (ritualistic gestures, motor speech) 5. Hyperorality and Dietary Changes (craving sweets, bingeing, altered food preferences) 6. Executive Deficits with Relative Sparing of Memory and Visuospatial Functions

💊 Pharmacological & Non-Pharmacological Management of FTD

There are currently no FDA-approved disease-modifying therapies for FTD. Management focuses on behavioral stabilization and symptom control.

⚠️ Avoid Acetylcholinesterase Inhibitors (AChEIs): Unlike AD, cholinesterase inhibitors (Donepezil) lack efficacy in FTD and can significantly worsen agitation, disinhibition, and behavioral symptoms.

SSRIs for Behavioral Control: Trazodone and SSRIs (Sertraline, Citalopram) improve serotonergic deficits in frontal cortex, helping reduce impulsivity, hyperorality, and compulsions.

Speech Therapy & AAC: Essential in Primary Progressive Aphasias to institute augmentative communication strategies early before speech output drops.

Caregiver Burnout Warning: FTD carries the highest caregiver strain among all dementias due to early profound personality changes and loss of social appropriateness.

Module 5 • Conceptual & Biological Paradigm Shift

Diagnostic Frameworks: Syndromal (DSM-5) vs Biological (2024 NIA-AA)

Explore the evolution from the DSM-5 functional clinical continuum (Mild vs. Major Neurocognitive Disorder) to the purely biological 2024 NIA-AA AT1T2NISV framework. This module also integrates the 13-item Hachinski Ischemic Score (HIS) Calculator to differentiate vascular dementia from primary neurodegenerative etiologies.

DSM-5 Neurocognitive Disorder Delineation

Diagnostic Category	Cognitive Decline Criteria	iADL Independence	Standardized Testing Range
Mild NCD (MCI)	Modest decline in $\ge 1$ domain (reported by patient, informant, or clinician)	Preserved (requires greater effort/compensatory strategies)	1.0 to 2.0 SD below normative mean (3rd–16th percentile)
Major NCD (Dementia)	Significant decline in $\ge 1$ domain (reported by patient, informant, or clinician)	Impaired (requires assistance with complex iADLs)	$\ge 2.0$ SD below normative mean (<3rd percentile)

2024 NIA-AA AT1T2NISV Biomarker Profile Purely Biological Framework

⚙️ Biological vs Clinical Diagnostic Simulator

Select biomarker findings and functional status to compute both DSM-5 syndromal classification and 2024 NIA-AA biological AD status.

A+ (Amyloid Positivity) T1+ (Early Tau / p-tau217) T2+ (Late Tau PET) (N)+ Neurodegeneration

Clinical Function & iADLs:

Module 6 • Disease-Modifying Biologics

Anti-Amyloid Immunotherapies & ARIA Safety Protocols

Review approved disease-modifying monoclonal antibodies—Lecanemab (Leqembi) and Donanemab (Kisunla)—for early AD. This module provides an interactive APOE Genotype ARIA Risk Calculator, delineates Donanemab's amyloid PET stopping rules, and charts the mandatory FDA MRI safety monitoring timeline.

Drug Protocols & Dosing Comparison

Lecanemab (Leqembi) Target: Soluble Protofibrils

Dosing: 10 mg/kg IV infusion every 2 weeks continuous.

Mechanism: Prevents plaque growth by binding toxic soluble oligomers and protofibrils.

Donanemab (Kisunla) Target: Insoluble Plaque Core

Dosing: IV infusion every 4 weeks (700 mg x3 infusions, then 1400 mg q4w).

🛑 Unique Stopping Rule: Dosing may be suspended if Amyloid PET shows clearance to <11 Centiloids (single scan) or <25 Centiloids (2 consecutive scans).

⚠️ Critical Safety Warning: Concurrent therapeutic anticoagulants (e.g., warfarin, DOACs) or thrombolytics dramatically increase risk of fatal intracerebral hemorrhage. Highly contraindicated.

APOE $\epsilon$4 Genotype ARIA Risk Visualizer

ARIA-E & ARIA-H

Amyloid-Related Imaging Abnormalities (sulcal edema ARIA-E / microhemorrhages ARIA-H) correlate directly with APOE $\epsilon$4 gene dose.

Select Patient APOE Genotype:

Mandatory FDA Radiological MRI Surveillance Pathway

1. Baseline MRI Must be obtained within 1 year prior to treatment start (FLAIR + GRE/SWI sequence).

2. Scheduled Scans Safety MRIs prior to Infusions 2, 3, 4, and 7 (Donanemab protocol).

3. Mild ARIA Action Asymptomatic mild ARIA-E allows cautious continued dosing under close MRI tracking.

4. Severe/Symptomatic Suspend dosing immediately for moderate/severe ARIA or clinical symptoms (headache, confusion).

Module 7 • Targeted Psychopharmacology

Management of Neuropsychiatric Symptoms & Brexpiprazole Titration

Neuropsychiatric symptoms (agitation, psychosis, apathy) accelerate decline and caregiver burnout. This module features an interactive dosing and titration engine for Brexpiprazole (Rexulti)—the FDA-approved agent for Alzheimer's agitation—and details critical safety guidelines, organ impairment dose caps, and subtype-specific neuroleptic sensitivities.

Brexpiprazole Titration Schedule & Organ Adjuster

FDA Approved for AD Agitation

Select patient metabolic and organ parameters to dynamically adjust maximum daily target doses.

Hepatic Function:

Renal Function (CrCl):

CYP2D6 / CYP3A4 Metabolizer Status:

Mechanism: Partial agonist at 5-HT1A and D2 receptors; antagonist at 5-HT2A. D2 partial agonism prevents total dopamine blockade, reducing extrapyramidal symptoms.

🚫 Class Black Boxed Warnings

Increased Mortality: Elderly patients with dementia-related psychosis treated with antipsychotics face elevated mortality risk (cardiovascular/infection).
Cerebrovascular Events: Higher stroke and TIA incidence observed.
Contraindications: Explicitly NOT indicated for PRN chemical restraint or psychosis without agitation.

Non-AD Dementia Psychiatric Management

Dementia with Lewy Bodies (DLB): Extreme neuroleptic sensitivity in up to 50% of patients. Typical/atypical antipsychotics can precipitate fatal parkinsonian crisis or NMS. Cholinesterase inhibitors are first-line for DLB hallucinations.

Behavioral Variant FTD (bvFTD): Antipsychotics ineffective and AChEIs contraindicated. SSRIs (Sertraline, Trazodone) are used to bolster frontal serotonergic tone.

Module 8 • Non-Pharmacological Prophylaxis

Multidomain Lifestyle Interventions & Vascular Control

Epidemiological evidence shows that 45% of global dementia cases are driven by 14 modifiable lifestyle factors. Explore the landmark FINGER Trial protocol and the SPRINT-MIND intensive blood pressure target data demonstrating significant preservation of executive function and cerebral microvascular integrity.

SPRINT-MIND Blood Pressure Thresholds

Vascular Optimization

Intensive systolic blood pressure control significantly reduces new-onset Mild Cognitive Impairment.

Key Takeaway: Targeting SBP <120 mmHg achieved a 19% reduction in MCI risk compared to standard target (<140 mmHg), protecting microvascular perfusion.

The 5 Pillars of the FINGER Trial Protocol

Multidomain Success

Simultaneous target intervention yielded 0.243 SD/yr cognitive score improvement (vs 0.213 control) across all subgroups regardless of APOE $\epsilon$4 status.

1. Diet (MIND Model) Leafy greens, berries, olive oil, nuts; restricted saturated fats and sugars.

2. Exercise Program Progressive aerobic and strength training targeting neurovascular health.

3. Cognitive Training Computerized exercises targeting processing speed, memory, and executive function.

4. Social Activity Structured group sessions preventing isolation, depression, and apathy.

5. Vascular / Metabolic Management Rigorous medical monitoring of lipids, body mass index, and glucose.

Global Impact: Reduced multi-morbidity risk by 60% and significantly lowered emergency hospital admissions. Currently expanded globally via the World Wide FINGERS (WW-FINGERS) network.

NeuroCognition Explorer